FindTrial
Sign In

A clinical trial of DNA methylation markers for cervical cancer risk stratification in HPV-positive patients

A clinical trial of DNA methylation for cervical cancer risk stratification in HPV-positive patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055993
Enrollment
Unknown
Registered
2022-01-30
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

Gold Standard:colposcopy and/or clinicopathological diagnosis
Index test:Specific DNA methylation markers

Sponsors

International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Females aged 18 years and over, with a history of sexual life and not during pregnancy; 2. HPV test at this medical institution, and the result is hrHPV positive; 3. Cervical exfoliation cytology examination performed in this medical institution, and qualified cytological pathological results; 4. Colposcopy and/or clinicopathological diagnosis in this medical institution.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Women with immunodeficiency; 3. Women with a history of other gynecological malignancies and tumors; 4. Women with a history of high-grade cervical lesions or surgery for cervical cancer, and a history of other malignant tumors.

Design outcomes

Primary

MeasureTime frame
DNA Methylation Markers;—

Countries

China

Contacts

Public ContactWang Yudong

International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University School of Medicine

owangyudong@126.com+86 18017316053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026